NEW YORK (GenomeWeb) – Oxford Gene Technology is looking to expand its presence in the next-generation sequencing market by building out its portfolio of optimized content for custom cancer panels.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering, with new content available for genes and regions linked to colorectal, lung, and prostate cancers, as well as glioma, melanoma, and sarcoma.
This adds to a catalog that already included content for chronic lymphocytic leukemia, acute myeloid leukemia, as well as ovarian and breast cancer. OGT first introduced its SureSeq myPanel offering last October.
In total, its menu now covers 70 genes. The panels are designed for use on Illumina instruments.
Emma Shipstone, executive vice president of marketing at the Oxford-based company, said that OGT is targeting clinical research laboratories with its products, especially those that are either disappointed with the performance of amplicon sequencing panels, or that still rely on Sanger sequencing to interrogate difficult cancer-associated genes. Some labs use both amplicon sequencing panels and Sanger to look at genes of interest.
“I think it’s something that amplicon-based panels have not been able to deliver on, and when it’s a